Alvotech and Cipla Medpro, a wholly-owned subsidiary of the leading global pharmaceutical company Cipla Limited (BSE: 500087; NSE: CIPLA EQ; hereafter referred to as "Cipla"), have entered into an exclusive partnership to bring key biosimilars to patients in emerging markets such as South Africa. The biosimilar portfolio will include five biosimilar medicines – two for oncology and three for treating auto-immune diseases.
“We’re delighted to establish this important partnership with Cipla, who is an ideal commercial partner, with a leading presence in the South African pharmaceutical market. Together we will provide patients with better access to high quality and cost-effective biosimilar medicines.”
Under the partnership, Alvotech will be responsible for development and supply of the products, while Cipla will be responsible for the registration and commercialization.
“We are happy to partner with Alvotech as this significantly adds to our portfolio of offerings in the global biosimilars space. This is in line with our purpose of Caring for life and ensuring accessible and effective treatment options to patients.”
About Cipla
Established in 1935, Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in our home markets of India, South Africa, North America, and key regulated and emerging markets. Our strengths in the respiratory, antiretroviral, urology, cardiology, anti-infective and CNS segments are well-known.
Our 46 manufacturing sites around the world produce 50+ dosage forms and 1,500+ products using cutting-edge technology platforms to cater to our 80+ markets. Cipla is ranked third largest in pharma in India (IQVIA MAT Dec’19), third largest in the pharma private market in South Africa (IQVIA MAT Dec’19), and is among the most dispensed generic players in the U.S.
